Trial Profile
The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Feb 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone; Melphalan
- Indications Multiple myeloma; Plasmacytoma
- Focus Therapeutic Use
- 22 Feb 2023 Status changed from active, no longer recruiting to completed.
- 09 Feb 2022 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 09 Feb 2022 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2022.